ArticleCancer cell2021
Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients.
Abstract read
In one paragraph
Article in Cancer cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 3 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Association of immune checkpoint inhibitors with SARS-CoV-2 infection rate and prognosis in patients with solid tumors: a systematic review and meta-analysis.Frontiers in immunology · 2024Pooled it
- Covid-19 and non-communicable diseases: evidence from a systematic literature review.BMC public health · 2021Pooled it
- Guideline
- Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients.Blood cancer journal · 2022Trial
- Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.The lancet. HIV · 2021Trial
- Coordinated immune response distinguishes duration of SARS-CoV-2 viral particle shedding in humans.iScience · 2026Article
- CORSA study finds spike-specific blunted immune responses in lymphoma patients after SARS-CoV-2 vaccine.Frontiers in immunology · 2026Article
- Article
- Dysregulated Adaptive Immune Responses to SARS-CoV-2 in Immunocompromised Individuals.Microorganisms · 2025Article
- Impact of chemotherapy on humoral and cellular immune responses to COVID-19 vaccination in patients with solid tumors.Frontiers in immunology · 2025Article
- Article
- Factors Associated with IgG/IgM Levels after SARS-CoV-2 Vaccination in Patients with Head and Neck Cancer.Tropical medicine and infectious disease · 2024Article
- Article
- Cytokine-responsive T- and NK-cells portray SARS-CoV-2 vaccine-responders and infection in multiple myeloma patients.Leukemia · 2024Article
- The Impact COVID-19 Infection on Cancer Patients: A Tertiary Cancer Center Experience in Jordan.Cureus · 2023Article
- Microfluidic Immuno-Serolomic Assay Reveals Systems Level Association with COVID-19 Pathology and Vaccine Protection.Small methods · 2023Article
- Were cancer patients worse off than the general population during the COVID-19 pandemic? A population-based study from Norway, Denmark and Iceland during the pre-vaccination era.The Lancet regional health. Europe · 2023Article
- Vector-based SARS-CoV-2 vaccination is associated with improved T-cell responses in hematological neoplasia.Blood advances · 2023Article
- Article
- Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
51 authors.
Sultan Abdul-JawadSchool of Cancer & Pharmaceutical Sciences, King's College London, London, UK.
Luca BaùInstitute of Biomedical Engineering, University of Oxford, Oxford, UK.
Thanussuyah AlaguthuraiSchool of Cancer & Pharmaceutical Sciences, King's College London, London, UK; Breast Cancer Now Research Unit, King's College London, London, UK.
Irene Del Molino Del BarrioCancer Immunotherapy Accelerator, UCL Cancer Institute, University College and King's College, London, UK; Peter Gorer Department of Immunobiology, King's College London, London, UK.
Adam G LaingPeter Gorer Department of Immunobiology, King's College London, London, UK.
Thomas S HaydayPeter Gorer Department of Immunobiology, King's College London, London, UK.
Leticia MoninThe Francis Crick Institute, London, UK.
Miguel Muñoz-RuizThe Francis Crick Institute, London, UK.
Louisa McDonaldOncology and Haematology Clinical Trials (OHCT), Guy's and St Thomas' NHS Foundation Trust, London UK.
Isaac Francos QuijornaWolfson Centre for Age-Related Diseases, IoPPN, King's College London, London, UK.
Duncan McKenzieThe Francis Crick Institute, London, UK.
Richard DavisPeter Gorer Department of Immunobiology, King's College London, London, UK.
Anna LorencPeter Gorer Department of Immunobiology, King's College London, London, UK.
Julie Nuo En ChanSchool of Cancer & Pharmaceutical Sciences, King's College London, London, UK.
Sarah RyanDepartment of Inflammation Biology, King's College London, London, UK.
Eva Bugallo-BlancoSchool of Cancer & Pharmaceutical Sciences, King's College London, London, UK.
Rozalyn YorkeDepartment of Inflammation Biology, King's College London, London, UK.
Shraddha KamdarPeter Gorer Department of Immunobiology, King's College London, London, UK.
Matthew FishPeter Gorer Department of Immunobiology, King's College London, London, UK; Department of Intensive Care Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Iva ZlatarevaPeter Gorer Department of Immunobiology, King's College London, London, UK.
Pierre VantouroutPeter Gorer Department of Immunobiology, King's College London, London, UK.
Aislinn JenningsPeter Gorer Department of Immunobiology, King's College London, London, UK; Department of Intensive Care Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Sarah GeePeter Gorer Department of Immunobiology, King's College London, London, UK.
Katie DooresDepartment of Infectious Diseases, King's College London, London, UK.
Katharine BaileyDepartment of Haematology, Guy's and St Thomas' NHS Foundation trust, London, UK.
Sophie HazellDepartment of Haematology, Guy's and St Thomas' NHS Foundation trust, London, UK.
Julien De NauroisDepartment of Medical Oncology Guy's and St Thomas' NHS Foundation Trust, London, UK.
Charlotte MossDepartment of Translational Oncology & Urology Research (TOUR), King's College London, London, UK.
Beth RussellDepartment of Translational Oncology & Urology Research (TOUR), King's College London, London, UK.
Aadil A KhanTargeted Therapy Team, The Institute of Cancer Research, London, UK.
Mark RowleyLondon Institute for Mathematical Sciences, Mayfair, London, UK; Saddle Point Science Ltd, London, UK.
Reuben BenjaminSchool of Cancer & Pharmaceutical Sciences, King's College London, London, UK; Department of Haematological Medicine, King's College Hospital, London, UK.
Deborah EntingDepartment of Translational Oncology & Urology Research (TOUR), King's College London, London, UK.
Doraid AlrifaiDepartment of Medical Oncology Guy's and St Thomas' NHS Foundation Trust, London, UK.
Yin WuSchool of Cancer & Pharmaceutical Sciences, King's College London, London, UK; Cancer Immunotherapy Accelerator, UCL Cancer Institute, University College and King's College, London, UK; Peter Gorer Department of Immunobiology, King's College London, London, UK; The Francis Crick Institute, London, UK.
You ZhouSystems Immunity University Research Institute and Division of Infection and Immunity, Cardiff University, Cardiff, UK.
Paul BarberSchool of Cancer & Pharmaceutical Sciences, King's College London, London, UK.
Tony NgSchool of Cancer & Pharmaceutical Sciences, King's College London, London, UK.
James SpicerSchool of Cancer & Pharmaceutical Sciences, King's College London, London, UK.
Mieke Van HemelrijckDepartment of Translational Oncology & Urology Research (TOUR), King's College London, London, UK.
Mayur KumarDepartment of Gastroenterology, Princess Royal University Hospital, Kent, UK.
Jennifer VidlerDepartment of Haematological Medicine, King's College Hospital, London, UK.
Yadanar LwinDepartment of Haematological Medicine, King's College Hospital, London, UK.
Paul FieldsSchool of Cancer & Pharmaceutical Sciences, King's College London, London, UK; Department of Haematology, Guy's and St Thomas' NHS Foundation trust, London, UK.
Sophia N KaragiannisBreast Cancer Now Research Unit, King's College London, London, UK; St. John's Institute of Dermatology, King's College London, London, UK; NIHR Biomedical Research Centre, and King's College London, London, UK.
Anthony C C CoolenTargeted Therapy Team, The Institute of Cancer Research, London, UK; London Institute for Mathematical Sciences, Mayfair, London, UK; Saddle Point Science Ltd, London, UK; Department of Biophysics, Radboud University, Nijmegen, The Netherlands.
Anne RiggDepartment of Medical Oncology Guy's and St Thomas' NHS Foundation Trust, London, UK.
Sophie PapaSchool of Cancer & Pharmaceutical Sciences, King's College London, London, UK; Department of Medical Oncology Guy's and St Thomas' NHS Foundation Trust, London, UK.
Adrian C HaydayPeter Gorer Department of Immunobiology, King's College London, London, UK; The Francis Crick Institute, London, UK.
Piers E M PattenSchool of Cancer & Pharmaceutical Sciences, King's College London, London, UK; Department of Haematological Medicine, King's College Hospital, London, UK; Medical Research Council (MRC) Clinical Academic Research Partnership, London, UK.
Sheeba IrshadSchool of Cancer & Pharmaceutical Sciences, King's College London, London, UK; Breast Cancer Now Research Unit, King's College London, London, UK; Department of Medical Oncology Guy's and St Thomas' NHS Foundation Trust, London, UK; Cancer Research UK (CRUK) Clinician Scientist, London, UK. Electronic address: sheeba.irshad@kcl.ac.uk.
Funding
Cancer Research UK 16463Cancer Research UK 20265Cancer Research UK 24869Medical Research Council MR/L006278/1Medical Research Council MR/L023091/1Medical Research Council MR/T005106/1
Abstract
Given the immune system's importance for cancer surveillance and treatment, we have investigated how it may be affected by SARS-CoV-2 infection of cancer patients. Across some heterogeneity in tumor type, stage, and treatment, virus-exposed solid cancer patients display a dominant impact of SARS-CoV-2, apparent from the resemblance of their immune signatures to those for COVID-19
Indexed as
AdultAgedAged, 80 and overCOVID-19FemaleHematologic NeoplasmsHumansImmunophenotypingMaleMiddle AgedNasopharynxNeoplasmsSevere Acute Respiratory SyndromeT-LymphocytesVirus SheddingYoung AdultantibodiescancerCOVID-19hemato-oncologicalimmuneSARS-CoV-2seroconversionvaccinevirus shedding
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.